Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: James Baker who wrote (3542)	6/16/1998 8:30:00 AM
From: James Baker	Respond to of 9523

Highlight this portion of favorable INDEPENDENT MUSE study: ''MUSE is a good treatment option for men with diabetes and/or vascular disease especially because it has few systemic side effects,'' said Kenneth Snow, MD, Medical Director of the Joslin-Lahey Diabetes & Endocrinology Center in Peabody, MA and a lead investigator in this trial. The authors also concluded that MUSE appears to be more effective in men over the age of 50 and perhaps more effective in men with organic risk factors, as opposed to psychological factors. Approximately 80% of all cases of erectile dysfunction are believed to have a physiological origin. The investigators also noted that patient education is critical to the success of the treatment. >>>>>>>>>> Joslin is one of the premiere diabetic clinics in the world! The importance of patient education is emphasized. This is a point I have made with Urologists online who have not been getting this kind of result with MUSE. Let's give all patients the same degree of good patient care. Jim